Zimmer Biomet (ZBH) is a publicly traded Healthcare sector company. As of May 20, 2026, ZBH trades at $85.64 with a market cap of $16.47B and a P/E ratio of 24.44. ZBH moved -0.94% today. Year to date, ZBH is -7.85%; over the trailing twelve months it is -10.46%. Its 52-week range spans $79.12 to $114.72. Analyst consensus is neutral with an average price target of $97.08. Rallies surfaces ZBH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zimmer Biomet lifts 2026 buyback expectation to $1 billion, up $250 million: Zimmer Biomet said it now expects to repurchase up to $1.0 billion of stock in fiscal 2026, raising its prior assumption by $250 million. The update was announced May 12, 2026 and is to be executed under its existing $1.5 billion authorization.
| Metric | Value |
|---|---|
| Price | $85.64 |
| Market Cap | $16.47B |
| P/E Ratio | 24.44 |
| EPS | $3.56 |
| Dividend Yield | 0.24% |
| 52-Week High | $114.72 |
| 52-Week Low | $79.12 |
| Volume | 2.03M |
| Avg Volume | 0 |
| Revenue (TTM) | $8.23B |
| Net Income | $705.10M |
| Gross Margin | 69.70% |
16 analysts cover ZBH: 0 strong buy, 4 buy, 11 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $97.08.